GPER1-mediated immunomodulation and neuroprotection in the myenteric plexus of a mouse model of Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Neurobiology of Disease

• Publication date

  2015-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.nbd.2015.05.017PMID 26051538
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Partial depletion of the proinflammatory monocyte population is neuroprotective in the myenteric plexus but not in the basal ganglia in a MPTP mouse model of Parkinson's disease.

  2015cited by this paper
• Progression of intestinal permeability changes and alpha‐synuclein expression in a mouse model of Parkinson's disease

  2014cited by this paper
• Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease.

  2013cited by this paper
• Colonic inflammation in Parkinson's disease.

  2013cited by this paper
• Mice overexpressing wild‐type human alpha‐synuclein display alterations in colonic myenteric ganglia and defecation

  2012cited by this paper
• Parkinson’s disease is not associated with gastrointestinal myenteric ganglion neuron loss

  2012cited by this paper
• Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system.

  2012cited by this paper
• Alpha‐synuclein in colonic submucosa in early untreated Parkinson's disease

  2012cited by this paper
• Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease

  2011cited by this paper
• Update in hormone therapy use in menopause.

  2011cited by this paper
• The critical role of the MyD88-dependent pathway in non-CNS MPTP-mediated toxicity.

  2011cited by this paper
• Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes.

  2010cited by this paper
• Clinical Criteria for the Diagnosis of Parkinson’s Disease

  2010cited by this paper
• When does Parkinson disease start?

  2010cited by this paper
• MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut.

  2010cited by this paper
• Colonic Biopsies to Assess the Neuropathology of Parkinson's Disease and Its Relationship with Symptoms

  2010cited by this paper
• Routine colonic biopsies as a new tool to study the enteric nervous system in living patients

  2009cited by this paper
• Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology.

  2009cited by this paper
• Neuroinflammation in Parkinson's disease: a target for neuroprotection?

  2009cited by this paper
• In vivo Effects of a GPR30 Antagonist

  2009cited by this paper
• Parkinson's Disease

  2009cited by this paper
• Neuroprotective actions of sex steroids in Parkinson's disease.

  2009cited by this paper
• Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis

  2009cited by this paper
• Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease.

  2009cited by this paper
• The second brain and Parkinson’s disease

  2009cited by this paper
• Medical records documentation of constipation preceding Parkinson disease

  2009cited by this paper
• Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide.

  2008cited by this paper
• In vivo characterization of estrogen receptor modulators with reduced genomic versus nongenomic activity in vitro.

  2008cited by this paper
• Parkinson’s disease and the gut: a well known clinical association in need of an effective cure and explanation

  2008cited by this paper
• Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease?

  2008cited by this paper
• Abnormal colonic motility in mice overexpressing human wild-type &agr;-synuclein

  2008cited by this paper
• Pathological lesions in colonic biopsies during Parkinson’s disease

  2008cited by this paper
• Minimization of PCR efficiency differences between standards and samples through dilution of PCR amplicons in reverse transcription buffer.

  2007cited by this paper
• The CD14+ CD16+ blood monocytes: their role in infection and inflammation

  2007cited by this paper
• The complex role of estrogens in inflammation.

  2007cited by this paper
• OESTROGEN AND NIGROSTRIATAL DOPAMINERGIC NEURODEGENERATION: ANIMAL MODELS AND CLINICAL REPORTS OF PARKINSON'S DISEASE

  2007cited by this paper
• Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease.

  2007cited by this paper
• Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6.

  2006cited by this paper
• Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.

  2006cited by this paper
• The need for neuroprotective therapies in Parkinson’s disease

  2006cited by this paper
• Timing of treatment initiation in Parkinson's disease: A need for reappraisal?

  2006cited by this paper
• Virtual and biomolecular screening converge on a selective agonist for GPR30

  2006cited by this paper
• Physiological Modulation of Intestinal Motility by Enteric Dopaminergic Neurons and the D2 Receptor: Analysis of Dopamine Receptor Expression, Location, Development, and Function in Wild-Type and Knock-Out Mice

  2006cited by this paper
• Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.

  2006cited by this paper
• The natural history of Parkinson’s disease

  2006cited by this paper
• Inflammation and neurodegeneration in Parkinson's disease.

  2004cited by this paper
• Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system

  2004cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Gastrointestinal dysfunction in Parkinson's disease.

  2003cited by this paper
• Gastrointestinal dysfunction in Parkinson's disease.

  2003cited by this paper
• Vasoactive intestinal peptide prevents activated microglia‐induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma

  2003cited by this paper
• Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

  2002cited by this paper
• Frequency of bowel movements and the future risk of Parkinson’s disease

  2001cited by this paper
• Cytokines in Parkinson's disease.

  2000cited by this paper
• Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice

  2000cited by this paper
• Cytokines in Parkinson’s Disease

  2000cited by this paper
• Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease.

  1996cited by this paper
• The natural history of Parkinson's disease

  1996cited by this paper
• Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease

  1996cited by this paper
• Cuprolinic blue (quinolinic phthalocyanine) counterstaining of enteric neurons for peroxidase immunocytochemistry.

  1995cited by this paper
• Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation.

  1995cited by this paper

• Raloxifene and Fulvestrant Exert Antioxidant, Anti‐Inflammatory, and Antiapoptotic Action Against Haloperidol‐Induced Tardive Dyskinesia in Rats via Activation of the GPER1/PI3k/Akt/Nrf2/HO‐1 Signaling Pathways

  2025cites this paper
• The interrelationship between intestinal immune cells and enteric α-synuclein in the progression of Parkinson’s disease

  2025cites this paper
• Targeting hormone-related signals to reprogram the antitumor immune response in breast cancer: Research progress and application prospects.

  2025cites this paper
• Enteric neuroprotection—A matter of balancing redox potentials, limiting inflammation, and boosting resilience

  2024cites this paper
• Unveiling the Potential of Estrogen: Exploring its Role in Neuropsychiatric Disorders and Exercise Intervention.

  2024cites this paper
• Protective role of female estrogens and estrogen receptors especially GPER receptor activation on body systems and diseases: a review

  2024cites this paper
• Rebalance of mitophagy by inhibiting LRRK2 improves colon alterations in an MPTP in vivo model

  2024cites this paper
• Activation of GPER1 in macrophages ameliorates UUO-induced renal fibrosis

  2023cites this paper
• DIFFERENTIAL CONTRIBUTION OF ESTROGEN RECEPTORS TO THE INTESTINAL THERAPEUTIC EFFECTS OF 17β-ESTRADIOL IN A MURINE MODEL OF PARKINSON'S DISEASE.

  2022cites this paper
• Comparative G-Protein-Coupled Estrogen Receptor (GPER) Systems in Diabetic and Cancer Conditions: A Review

  2022cites this paper
• Involvement of the G-Protein-Coupled Estrogen Receptor-1 (GPER) Signaling Pathway in Neurodegenerative Disorders: A Review

  2022cites this paper
• Peripheral Neuroprotective and Immunomodulatory Effects of 5α-Reductase Inhibitors in Parkinson’s Disease Models

  2022cites this paper
• Estrogen Up-Regulates Iron Transporters and Iron Storage Protein Through Hypoxia Inducible Factor 1 Alpha Activation Mediated by Estrogen Receptor β and G Protein Estrogen Receptor in BV2 Microglia Cells

  2022cites this paper
• Differential Effects of the G-Protein-Coupled Estrogen Receptor (GPER) on Rat Embryonic (E18) Hippocampal and Cortical Neurons

  2022cites this paper
• Blood-based gene-expression biomarkers identification for the non-invasive diagnosis of Parkinson's disease using two-layer hybrid feature selection.

  2022cites this paper
• Nitric Oxide Regulates Estrus Cycle Dependent Colonic Motility in Mice

  2021cites this paper
• ERα36–GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells

  2021cites this paper
• Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment

  2021cites this paper
• Effect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model

  2021cites this paper
• Is there a halo-enzymopathy in Parkinson's disease?

  2021cites this paper
• MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson’s Disease

  2021cites this paper
• The Role of Intestinal Macrophages in Gastrointestinal Homeostasis: Heterogeneity and Implications in Disease

  2021cites this paper
• Neuroprotection Effect of Quercetin on TNF-α Levels and Gene Expression of Caspase 3 in MPTP-Induced Male NMRI Mice

  2020cites this paper
• Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease

  2020cites this paper
• The role of sex and sex Hormones in Neurodegenerative Diseases.

  2020cites this paper
• Diminished enteric neuromuscular transmission in the distal colon following experimental spinal cord injury.

  2020cites this paper
• STEROIDOGENIC MACHINERY IN THE ADULT RAT COLON.

  2020cites this paper
• G Protein-Coupled Estrogen Receptor in Immune Cells and Its Role in Immune-Related Diseases

  2020cites this paper
• Deletion of chr7p22 and chr15q11: Two Familial Cases of Immune Deficiency: Extending the Phenotype Toward Dysimmunity

  2019cites this paper
• Is there a halo-enzymopathy in Parkinson's disease?

  2019cites this paper
• Analysis of the Gut Microflora in Patients With Parkinson's Disease

  2019cites this paper
• Localization of estrogen receptor ERα, ERβ and GPR30 on myenteric neurons of the gastrointestinal tract and their role in motility.

  2019cites this paper
• Hypothalamic paraventricular nucleus neurons activated by estrogen GPER1 receptors promote anti-inflammation effects in the early stage of colitis.

  2019cites this paper
• Effects of progesterone at the enteric level in a mouse model of Parkinson's disease

  2019influential citation
• Twice subacute MPTP administrations induced time-dependent dopaminergic neurodegeneration and inflammation in midbrain and ileum, as well as gut microbiota disorders in PD mice.

  2019cites this paper
• Neuroprotection and immunomodulation in the gut of parkinsonian mice with a plasmalogen precursor.

  2019cites this paper
• Role of estrogens in fish immunity with special emphasis on GPER1.

  2018cites this paper
• Tyrosine hydroxylase as a sentinel for central and peripheral tissue responses in Parkinson's progression: Evidence from clinical studies and neurotoxin models.

  2018cites this paper
• Excess amounts of 3‐iodo‐l‐tyrosine induce Parkinson‐like features in experimental approaches of Parkinsonism

  2018cites this paper
• The Role of GPER Signaling in Carcinogenesis: A Focus on Prostate Cancer

  2018cites this paper
• The estrogen-macrophage interplay in the homeostasis of the female reproductive tract.

  2018cites this paper
• Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson’s Disease

  2018cites this paper
• Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.

  2018cites this paper
• GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease

  2017cites this paper
• Progranulin gene delivery reduces plaque burden and synaptic atrophy in a mouse model of Alzheimer's disease

  2017cites this paper
• Analysis of Gut Microbiota in Patients with Parkinson’s Disease

  2017cites this paper
• GPR30 Activation Contributes to the Puerarin-Mediated Neuroprotection in MPP+-Induced SH-SY5Y Cell Death

  2016cites this paper
• Neuroactive gonadal drugs for neuroprotection in male and female models of Parkinson's disease.

  2016cites this paper
• Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice

  2016cites this paper
• Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse model of Parkinson's disease.

  2016influential citation
• Stress, sex, and the enteric nervous system

  2016cites this paper